• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by Aktis Oncology Inc.

    1/20/26 2:01:01 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKTS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    Aktis Oncology, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    01021M104

    (CUSIP Number)


    Anthony J. Caldwell, Esq.
    Shartsis Friese LLP, 425 Market Street, 11th Floor
    San Francisco, CA, 94105
    (415) 421-6500

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    01/12/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    01021M104


    1 Name of reporting person

    EcoR1 Capital, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,824,469.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,824,469.00
    11Aggregate amount beneficially owned by each reporting person

    4,824,469.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.1 %
    14Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:
    Percentage calculated based on 53,296,950 shares of Common Stock outstanding following the Issuer's initial public offering, as reported in the prospectus filed by the Issuer on January 9, 2026.


    SCHEDULE 13D

    CUSIP No.
    01021M104


    1 Name of reporting person

    Oleg Nodelman
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    37,866.00
    8Shared Voting Power

    4,824,469.00
    9Sole Dispositive Power

    37,866.00
    10Shared Dispositive Power

    4,824,469.00
    11Aggregate amount beneficially owned by each reporting person

    4,862,335.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.1 %
    14Type of Reporting Person (See Instructions)

    IN, HC

    Comment for Type of Reporting Person:
    The shares reported herein include 37,866 shares of Common Stock issuable under stock options granted to Mr. Nodelman in his capacity as a director of the Issuer. 1/36th of the original number of shares subject to the option shall vest in monthly installments from January 8, 2026, subject to Mr. Nodelman's continuous service through each vesting date, inclusive. Percentage calculated based on 53,296,950 shares of Common Stock outstanding following the Issuer's initial public offering, as reported in the prospectus filed by the Issuer on January 9, 2026.


    SCHEDULE 13D

    CUSIP No.
    01021M104


    1 Name of reporting person

    EcoR1 Capital Fund Qualified, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,348,658.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,348,658.00
    11Aggregate amount beneficially owned by each reporting person

    4,348,658.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.2 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Percentage calculated based on 53,296,950 shares of Common Stock outstanding following the Issuer's initial public offering, as reported in the prospectus filed by the Issuer on January 9, 2026.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock
    (b)Name of Issuer:

    Aktis Oncology, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    17 DRYDOCK AVENUE, SUITE #17-401, BOSTON, MASSACHUSETTS , 02210.
    Item 2.Identity and Background
    (a)
    The reporting persons are: EcoR1 Capital, LLC, a Delaware limited liability company ("EcoR1") EcoR1 Capital Fund Qualified, L.P., a Delaware limited partnership ("Qualified Fund") Oleg Nodelman Qualified Fund is filing this statement jointly with the other reporting persons, but not as a member of a group, and it expressly disclaims membership in a group. In addition, the filing of this Schedule 13D on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any securities covered by this Schedule 13D. Each reporting person also disclaims beneficial ownership of the securities reported herein except to the extent of that person's pecuniary interest therein.
    (b)
    357 Tehama Street #3, San Francisco, CA 94103
    (c)
    EcoR1 is an investment adviser to investment funds, including Qualified Fund (collectively, the "Funds"). EcoR1 is the general partner of the Funds. Mr. Nodelman is the manager and control person of EcoR1.
    (d)
    During the last five years, none of the reporting persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    During the last five years, none of the reporting persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    For citizenship of the reporting persons, see Item 6 of each reporting person's cover page.
    Item 3.Source and Amount of Funds or Other Consideration
     
    The Funds purchased 11,400,000 shares of the Issuer's Series A Redeemable Convertible Preferred Stock for an aggregate purchase price of $22,800,000, including $19,827,620 paid by Qualified Fund for 9,913,810 shares. The Funds purchased 2,500,000 shares of the Issuer's Series B Redeemable Convertible Preferred Stock for an aggregate purchase price of $10,000,000, including $9,590,000 paid by Qualified Fund for 2,397,500 shares. Immediately prior to the closing of the initial public offering of the Issuer's Common Stock on 1/12/2026, the shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock held by the Funds automatically converted on a 3.8044-for-1 basis into 2,602,247 shares of the Issuer's Common Stock and 1,051,412 shares of the Issuer's Class A Common Stock. No additional consideration was paid on such conversion. In addition, certain of the Funds purchased 2,222,222 shares of Common Stock in the Issuer's initial public offering on 1/12/2026 for an aggregate purchase price of $39,999,996. Qualified Fund purchased 2,077,779 of these shares for a purchase price of $37,400,022. The foregoing purchases of securities were all made from the Funds' working capital. On 1/8/2026, Mr. Nodelman received a grant of options to acquire 37,866 shares of the Issuer's Common Stock for his service on the Issuer's board of directors.
    Item 4.Purpose of Transaction
     
    Oleg Nodelman, the manager of EcoR1, is a member of the Issuer's board of directors. The reporting persons acquired securities of the Issuer for investment purposes based on their belief that the Issuer's securities represented an attractive investment opportunity. The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Common Stock and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, and other investment considerations. Depending on their evaluation of various factors, the reporting persons may take such actions regarding their holdings of the Issuer's securities as they deem appropriate in light of circumstances existing from time to time. Such actions may include purchasing additional Common Stock in the open market, through privately negotiated transactions with third parties or otherwise, converting shares of Class A Common Stock into shares of Common Stock and selling at any time, in the open market, through privately negotiated transactions with third parties or otherwise, all or part of the Common Stock or other securities that they now own or hereafter acquire. The reporting persons also may from time to time enter into or unwind hedging or other derivative transactions with respect to the Common Stock or pledge their interests in the Common Stock and other securities to obtain liquidity. In addition, from time to time the reporting persons and their representatives and advisers may communicate with other stockholders, industry participants and other interested parties about the Issuer. The reporting persons have no present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. However, as noted above, Mr. Nodelman serves on the Issuer's board of directors, and the reporting persons may recommend action to the Issuer's management, board of directors and stockholders. Any such actions could involve one or more of the events referred to in clauses (a) through (j) of Item 4 of Schedule 13D, including, potentially, one or more mergers, consolidations, sales or acquisitions of assets, changes in control, issuances, purchases, dispositions or pledges of securities or other changes in capitalization.
    Item 5.Interest in Securities of the Issuer
    (a)
    EcoR1: 4,824,469 Oleg Nodelman: 4,862,335 Qualified Fund: 4,348,658 Aggregate percentage of the class of Common Stock beneficially owned by the reporting persons: EcoR1: 9.1% Oleg Nodelman: 9.1% Qualified Fund: 8.2%
    (b)
    (i) Sole power to vote or to direct the vote: EcoR1: 0 Oleg Nodelman: 37,866 Qualified Fund: 0 (ii) Shared power to vote or to direct the vote: EcoR1: 4,824,469 Oleg Nodelman: 4,824,469 Qualified Fund: 4,348,658 (iii) Sole power to dispose or to direct the disposition of: EcoR1: 0 Oleg Nodelman: 37,866 Qualified Fund: 0 (iv) Shared power to dispose or to direct the disposition of: EcoR1: 4,824,469 Oleg Nodelman: 4,824,469 Qualified Fund: 4,348,658
    (c)
    In the 60 days preceding the date of this Schedule 13D, the reporting persons engaged in the transactions in the Issuer's Common Stock described in Item 3 above.
    (d)
    Not applicable.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    EcoR1 is the investment adviser to its clients pursuant to investment management agreements or limited partnership agreements providing to EcoR1 the authority, among other things, to invest the funds of such clients in Stock, to vote and dispose of Stock and to file this statement on behalf of such clients. Pursuant to such limited partnership agreements, EcoR1 is entitled to allocations based on assets under management and realized and unrealized gains. Pursuant to such investment management agreements, EcoR1 is entitled to fees based on assets under management and realized and unrealized gains. The Funds hold the aggregate amount of 1,051,412 shares of the Issuer's Class A Common Stock. Each share of Class A Common Stock is convertible into one share of the Issuer's Common Stock at the holder's election, provided that the shares may not be converted if doing so would result in EcoR1 or any of the Funds beneficially owning more than 4.99% of the outstanding shares of Common Stock. Due to this limitation, the shares of Class A Common Stock held by the Funds are not presently convertible. The Funds are party to a Third Amended and Restated Investors' Rights Agreement, dated September 20, 2024, with the Issuer (the "Rights Agreement"). The Rights Agreement grants certain rights to the Funds, including certain demand, piggyback and Form S-3 registration rights with respect to the registrable securities held by them. The terms and provisions of the Rights Agreement are described more fully in the Issuer's Registration Statement on Form S-1/A (File No. 333-292283) declared effective by the Commission on January 7, 2026 (the "Registration Statement"), and the above summary is qualified by reference to such description and the full text of the Rights Agreement, which is filed as Exhibit 99.2 to this Schedule 13D and is incorporated herein by reference. In connection with the initial public offering of the Issuer's Common Stock, each of the Funds and Mr. Nodelman has entered into lock-up agreements, pursuant to which each of them have agreed, subject to certain exceptions, not to sell, transfer or otherwise convey any of the Issuer's securities held by the Funds for 180 days following the date of the offering. The terms and provisions of such lock-up agreements are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the lock-up agreement, a form of which is filed as Exhibit 99.3 to this Schedule 13D and is incorporated herein by reference. Mr. Nodelman, in his capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant to the Issuer's 2026 Equity Incentive Plan (the "2026 Plan"), and the Issuer's non-employee director compensation policy (the "Compensation Plan"). The terms and provisions of the 2026 Plan and the Compensation Plan are described in the Registration Statement, and the above summary is qualified by reference to such description and the full text of which is filed as Exhibit 99.4 and Exhibit 99.5 to this Schedule 13D and are incorporated herein by reference. In addition, the Issuer has entered into an indemnification agreement with each of its directors and executive officers, including Mr. Nodelman. The indemnification agreement requires the Issuer, among other things, to indemnify Mr. Nodelman for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his services as director. The terms and provisions of the indemnification agreement are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the Registration Statement, which is filed as Exhibit 99.6 to this Schedule 13D and is incorporated herein by reference.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 99.1: Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. Exhibit 99.2: Third Amended and Restated Investors' Rights Agreement, dated as of September 20, 2024 (filed as Exhibit 4.1 to the Issuer's Registration Statement on Form S-1/A as filed with the Commission on January 7, 2026 (SEC File No. 333-292283) and incorporated herein by reference). Exhibit 99.3: Form of Lock-Up Agreement for certain directors, officers and other stockholders of the Issuer (filed as part of Exhibit 1.1 to the Issuer's Registration Statement on Form S-1/A as filed with the Commission on January 7, 2026 (SEC File No. 333-292283) and incorporated herein by reference). Exhibit 99.4: 2026 Equity Incentive Plan, as amended, and associated forms (filed as Exhibit 10.2 to the Issuer's Registration Statement on Form S-1/A as filed with the Commission on January 7, 2026 (SEC File No. 333-292283) and incorporated herein by reference). Exhibit 99.5: Non-Employee Director Compensation Policy, as amended, and associated forms (filed as Exhibit 10.5 to the Issuer's Registration Statement on Form S-1/A as filed with the Commisson on January 7, 2026 (SEC File No. 333-292283) and incorporated herein by reference). Exhibit 99.6: Form of Indemnification Agreement (filed as Exhibit 10.6 to the Issuer's Registration Statement on Form S-1/A as filed with the Commission on January 7, 2026 (SEC File No. 333-292283) and incorporated herein by reference).

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    EcoR1 Capital, LLC
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager
    Date:01/20/2026
     
    Oleg Nodelman
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Reporting person
    Date:01/20/2026
     
    EcoR1 Capital Fund Qualified, L.P.
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
    Date:01/20/2026
    Get the next $AKTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTS

    DatePrice TargetRatingAnalyst
    1/4/2024$2.00 → $1.00Overweight → Neutral
    Piper Sandler
    9/6/2023$9.25 → $1.75Buy → Neutral
    B. Riley Securities
    1/24/2023$9.25Buy
    B. Riley Securities
    11/2/2021$18.00 → $13.00Outperform
    Oppenheimer
    More analyst ratings

    $AKTS
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by Aktis Oncology Inc.

    SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)

    1/20/26 5:44:53 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13D filed by Aktis Oncology Inc.

    SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)

    1/20/26 2:01:01 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13D filed by Aktis Oncology Inc.

    SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)

    1/15/26 6:02:12 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the closing of its upsized initial public offering of 17,650,000 shares of its common stock, at an initial public offering price of $18.00 per share, occurred on January 12, 2026. In addition, the underwriters exercised in full their option to purchase an additional 2,647,500 shares of Aktis' common stock, at the initial public offering price of $18.00 per share. The sale of the 2,647,500 additi

    1/13/26 6:30:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

    Vida has partnered with Aktis since co-leading its Series A, supporting the company from discovery through IPO and establishing itself as one of Aktis' largest shareholders; Helen Kim, Vida Senior Managing Director, has served on the Board since 2021 Brian Goodman, Ph.D., Managing Director at Vida Ventures and Co-Founder of Aktis, served as founding Chief Operating Officer, helping to establish the company's early operational, scientific, and strategic foundation Vida Ventures ("Vida"), a next-generation life sciences venture firm, today congratulates Aktis Oncology (NASDAQ:AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for t

    1/9/26 12:58:00 PM ET
    $AKTS
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

    Charlotte, NC, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process Committed to Full Continuity in Delivering Next-Generation BAW High-Band RF Filters to Customers Around the World Filing to Ensure Business Sold Free and Clear of Qorvo Infringement Following Final Judgement and Required Cleansing Process Charlotte, NC – DECEMBER 16, 2024 – Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that it has voluntarily filed for chapter 11 relie

    12/16/24 1:22:01 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Eli Lilly & Co claimed ownership of 6,344,114 shares (SEC Form 3)

    3 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/15/26 6:01:45 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Foley Todd converted options into 4,002,533 shares and bought $4,191,660 worth of shares (232,870 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:20:21 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mpm Bioventures 2018, L.P. converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:19:26 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Foley Todd converted options into 4,002,533 shares and bought $4,191,660 worth of shares (232,870 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:20:21 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mpm Bioventures 2018, L.P. converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:19:26 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gadicke Ansbert converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:17:54 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Akoustis Technologies downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Akoustis Technologies from Overweight to Neutral and set a new price target of $1.00 from $2.00 previously

    1/4/24 7:14:42 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis Technologies downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Akoustis Technologies from Buy to Neutral and set a new price target of $1.75 from $9.25 previously

    9/6/23 1:54:09 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Akoustis Technologies with a new price target

    B. Riley Securities initiated coverage of Akoustis Technologies with a rating of Buy and set a new price target of $9.25

    1/24/23 7:19:06 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Akoustis Technologies Inc.

    SC 13G/A - Akoustis Technologies, Inc. (0001584754) (Subject)

    11/12/24 1:34:05 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Akoustis Technologies Inc.

    SC 13G - Akoustis Technologies, Inc. (0001584754) (Subject)

    11/4/24 11:00:32 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Akoustis Technologies Inc.

    SC 13G - Akoustis Technologies, Inc. (0001584754) (Subject)

    2/13/24 4:58:48 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Financials

    Live finance-specific insights

    View All

    Akoustis Reports Third Quarter FY24 Results

    Q3 Revenue Up 7% Quarter-Over-Quarter Filter-Related Revenue Up 13% Quarter-Over-Quarter, Third Highest in Company History Growth, Cost Savings Initiatives, CHIPS Act ITC Refund Support Operating Cash Flow Breakeven in Next Nine MonthsRobust Customer Activity in Wi-Fi AP, 5G Infrastructure, Defense, Timing Control, Semiconductor Back-End Services Company to Host Investor Update Call Today at 8:00 am ET Charlotte, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, t

    5/13/24 7:30:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis to Webcast Q3FY24 Results on May 13 at 8:00 am ET

    Charlotte, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, will webcast its Q3FY24 results on Monday, May 13, 2024, at 8:00 am Eastern Time. Management will host a question-and-answer session at the end of the call. To listen to the call by telephone, please dial 877-407-3982 (domestic) or 201-493-6780 (international). The conference call will be webcast live on the Company's website and will be available for playback at the following URL: https://ir.akoustis.com/news-events/ir-calendar

    5/7/24 7:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis Reports Second Quarter FY24 Results

    Q2 Revenue Up 20% Year-Over-Year, In-Line with Prior Guidance Guiding Record Quarterly Revenue for the March Quarter—Up 18 to 25% SequentiallyGrowth, Cost Savings Initiatives, CHIPS Act ITC Refund Support Operating Cash Flow Breakeven in December QuarterRobust Customer Activity in Wi-Fi AP, 5G Infrastructure, Defense, Timing Control, Semiconductor Back-End Services Company to Host Investor Update Call Today at 8:00 am ET Charlotte, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, t

    2/13/24 7:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Leadership Updates

    Live Leadership Updates

    View All

    Akoustis Announces Leadership Transition

    Charlotte, NC, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Akoustis Announces Leadership Transition Charlotte, NC, August 8, 2024 (GLOBE NEWSWIRE) - Akoustis Technologies, Inc. (Nasdaq: AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today the mutually agreed resignation of Jeffery B. Shealy as Chief Executive Officer and as a member of the Board of Directors, effective August 6, 2024. Kamran Cheema, the Company's Chief Product Officer, will serve as interim Chief Executive Officer. Mr. Cheema has served as Chief Product Officer for the Company since 2022

    8/8/24 8:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis Appoints Michelle L. Petock, CEO of W Greig & Company, to its Board of Directors

    Charlotte, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that it has appointed Michelle L. Petock as a new member of its board of directors. The appointment brings the total number of board members to eight. Ms. Petock will serve on the Strategic Development Committee and the Audit Committee of the Company's board of directors. Jerry Neal, co-Chairman of the board, stated, "Ms. Petock is a welcome addition to our board given her extensive accomplishments in financ

    3/23/23 7:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis Appoints Ken Boller as Chief Financial Officer

    Charlotte, N.C., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced the appointment of Ken Boller as Chief Financial Officer. Mr. Boller joined the Company in 2017 as Corporate Controller and has served in the role of Interim Chief Financial Officer since 2018. Mr. Boller will continue to operate out of the North Carolina headquarters of Akoustis and will continue to lead the finance team in the new position. Prior to Akoustis, he was a Regional Controller and Corporate Director of

    2/10/22 7:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care